COYA (Coya Therapeutics) 3-Year EBITDA Growth Rate : -15.40% (As of Dec. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Coya Therapeutics 3-Year EBITDA Growth Rate?

Coya Therapeutics's EBITDA per Share for the three months ended in Dec. 2024 was $-0.25.

During the past 3 years, the average EBITDA Per Share Growth Rate was -15.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Coya Therapeutics was -15.40% per year. The lowest was -15.40% per year. And the median was -15.40% per year.

Competitive Comparison of Coya Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Coya Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Coya Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Coya Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Coya Therapeutics's 3-Year EBITDA Growth Rate falls into.

Save Embed

;

Save Embed

;

Coya Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Coya Therapeutics (NAS:COYA) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Coya Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Coya Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Coya Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Coya Therapeutics Inc (NAS:COYA) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

N/A

Address

5850 San Felipe Street, Suite 500, Houston, TX, USA, 77057

Website

https://www.coyatherapeutics.com

Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.

Executives

David S Snyder	officer: Chief Financial Officer	ONE SCIENCE COURT, MADISON WI 53711
Fred Grossman	officer: Chief Medical Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Ann Lee	director	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Dieter Weinand	director	C/O REPLIMUNE GROUP, INC., 18 COMMERCE WAY, WOBURN MA 01801
Goldstein Dov A Md	director
Adrian Hepner	officer: Chief Medical Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Hideki Garren	director	C/O PROTHENA BIOSCIENCES INC, 331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO CA 94080
Anabella Villalobos	director	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Howard Berman	director, 10 percent owner, officer: Chief Executive Officer	C/O COYA THERAPEUTICS, INC., 5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057
Bertex Llc	10 percent owner	5850 SAN FELIPE ST., SUITE 500, HOUSTON TX 77057